Improving the health and quality of life of patients is the goal of the research- driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of almost 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
|Amounts in millions of EUR,
unless otherwise indicated
|Asia, Australia, Africa||23%||27%|
|Research and development expenses||3,078||3,112||–1%|
|Average number of employees||49,610||45,692||+9%|
|Operating income as % of net sales||19.3%||18.1%|
|as % of net sales||–1.2%||11.7%|
|Return on Group equity||–2.0%||19.3%|
|Investments in tangible assets||872||645||+35%|
|Depreciation of tangible assets||521||516||+1%|